Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Authors: Luis G. Paz-Ares, Oscar Juan-Vidal, Giannis S. Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M. Patel, Takayuki Takahama, Scott P. Owen, Douglas M. Reznick, Firas B. Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino, Elizabeth Ahern, Venessa Chin, Stephen Della-Fiorentina, Kevin Jasas, Christos Karapetis, Jeremy Long, Louise Nott, Kenneth O'Byrne, Craig Underhill, Richard Greil, Maximilian Hochmair, Andreas Pircher, Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan Azambuja, Giuliano Borges, Gilberto Castro, Suellen Castro, Felipe Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier Valette, Jaafar Bennouna, Christos Chouaid, Alexis Cortot, Sebastien Couraud, Didier Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, Jeannick Madelaine, Marie Marcq, Emilie Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, Alain Vergnenegre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Athanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Cecilia Bettini, Matteo Brighenti, Giulio Cerea, Filippo De Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Hector Soto Parra, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi, Koichi Azuma, Tomohisa Baba, Yuka Fujita, Eiki Ichihara, Takashi Kasai, Terufumi Kato, Haruki Kobayashi, Shoichi Kuyama, Kazumi Nishino, Masahide Oki, Kyoichi Okishio, Tomohiro Sakamoto, Yuki Sato, Yuki Shinno, Takayuki Takahama, Koichi Takayama, Yasutaka Watanabe, Noriko Yanagitani, Yoshitaka Zenke, Daniel Motola Kuba, Tomas Daniel Pineda Razo, Robin Cornelissen, Lizza Hendriks, Jeroen Kloover, Klaar Maas, Cor van der Leest, Lubomir Bodnar, Boguslawa Karaszewska, Andrzej Mruk, Paula Alves, Antonio Araujo, Isabel Domingues, Ana da Conceicao Fernandes Rodrigues, Nuno Gil, Helena Magalhaes, Barbara Parente, Marcia Correa, Hector Velez-Cortes, Andres Aguilar Hernandez, Ruben Alonso Calderon, Joaquim Barrera, David Baz, Antonio Calles, Maria Campelo, Francisco Carpeno, Enric Costa, Manuel Dols, Manuel Domine Gomez, Miguel Fernandez de Sanmamed, Enriqueta Font, Jose Fuentes, Maria Pilar Garrido Lopez, Oscar Juan Vidal, Jose Larriba, Laia Martinez, Ramon Palmero Sanchez, Silverio Ros Martinez, Jon Zugazagoitia Fraile, Ahmet Bilici, Irfan Cicin, Umut Demirci, Yesim Eralp, Mahmut Gumus, Ozan Yazici, Shobhit Baijal, Katy Clarke, Farah Lim, Dakshinamoorthy Muthukumar, Nicola Steele, Yvonne Summers, Ahmed Abdelaziz, Eric Avery, Firas Badin, Charles Connor, Davey Daniel, Amir Faridi, January Fields-Meehan, Marina Garassino, Todd Gersten, Daniel Haggstrom, David Hakimian, William Houck, Henrik Illum, Roger Keresztes, Charles Kurkul, Charles Kuzma, Rachel Lerner, Steven Liu, Smitha Menon, Rami Owera, Vipul Patel, Ivor Percent, Andrew Piper, Sucharu Prakash, Douglas Reznick, Jorge Rios-Perez, Jun Sun, Restituto Tibayan, Anne Traynor, William Walsh, Donald Wender
Journal: Journal of Clinical Oncology (2024)

The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.